Skip to main content

3 Result(s)

within Raymond C. Wadlow Remove this filter

and

  1. No Access

    Article

    Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1

    Mutations in genes of the RAS family are preset on about 20% of human cancers, making RAS proteins prime potential targets for cancer therapy. Direct targeting of RAS proteins has not so far been productive, but ...

    David A. Barbie, Pablo Tamayo, Jesse S. Boehm, So Young Kim, Susan E. Moody… in Nature (2009)

  2. No Access

    Article

    A phase I and pharmacokinetic study of ganetespib (STA-9090) in advanced hepatocellular carcinoma

    Background Ganetespib (STA-9090) is an Hsp90 inhibitor that downregulates VEGFR, c-MET, HER2, IGF-IR, EGFR, and other Hsp90 client proteins involved in hepatocarcinogenesis, thereby making it an ...

    Lipika Goyal, Raymond C. Wadlow, Lawrence S. Blaszkowsky… in Investigational New Drugs (2015)

  3. No Access

    Article

    A phase 2 clinical trial of the heat shock protein 90 (HSP 90) inhibitor ganetespib in patients with refractory advanced esophagogastric cancer

    Subsets of esophagogastric (EG) cancers harbor genetic abnormalities, including amplification of HER2, MET, or FGFR2 or mutations in PIK3CA, EGFR, or BRAF. Ganetespib which is a novel triazolone heterocyclic i...

    Lipika Goyal, Surendra Pal Chaudhary, Eunice L. Kwak… in Investigational New Drugs (2020)